Report of Foreign Issuer (6-k)

Date : 08/14/2019 @ 12:01PM
Source : Edgar (US Regulatory)
Stock : Akari Therapeutics PLC (AKTX)
Quote : 1.79  -0.0342 (-1.87%) @ 7:09PM

Report of Foreign Issuer (6-k)





Washington, D.C. 20549


Form 6-K


Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934


August 2019


Commission file number: 001-36288


Akari Therapeutics, Plc

(Translation of registrant's name into English)


75/76 Wimpole Street

London W1G 9RT

United Kingdom

(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.


Form 20-F   x        Form 40-F  ¨


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____








On August 14, 2019, Akari Therapeutics, Plc (the “Company”) issued a press release announcing that the US Food and Drug Administration has granted Fast Track designation for nomacopan for the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.


In addition, on August 13, 2019, Dov Elefant notified the Company of his decision to resign as Chief Financial Officer of the Company, after over 7 years with the Company, in order to accept another opportunity. Mr. Elefant has agreed to assist in the smooth transition of his duties and his last day is expected to be in mid-September. The Company thanks Mr. Elefant for his many years of service and contributions to the Company.


The information in this Form 6-K including the first paragraph of Exhibit 99.1 is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.


Exhibit No.


99.1 Press Release dated August 14, 2019.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


  Akari Therapeutics, Plc  
  By: /s/ Clive Richardson  
  Name:   Clive Richardson  
    Interim Chief Executive Officer and
Chief Operating Officer


Date: August 14, 2019



Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart

1 Year : From Nov 2018 to Nov 2019

Click Here for more Akari Therapeutics Charts.

Akari Therapeutics (NASDAQ:AKTX)
Intraday Stock Chart

Today : Monday 11 November 2019

Click Here for more Akari Therapeutics Charts.

Latest AKTX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.